ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "Rituximab"

  • Abstract Number: 008 • 2020 Pediatric Rheumatology Symposium

    Incidence and Risk Factors of Hypogammaglobulinemia and Infectious Complications Associated with Rituximab Use in Pediatric Rheumatic Diseases

    Mei-Sing Ong1, Deborah Rothman 2 and Marc Natter 3, 1Harvard Medical School & Harvard Pilgrim Healthcare Institute, Boston, 2Massachusetts General Hospital, Springfield, 3Boston Children's Hospital, Boston

    Background/Purpose: B-cell depletion therapy has increasingly been used for the treatment of childhood-onset rheumatic diseases. Previous studies investigating whether rituximab results in increased infections have…
  • Abstract Number: 068 • 2020 Pediatric Rheumatology Symposium

    Development of CARRA Consensus Treatment Plans for Severe ANCA-associated Vasculitis – Final CARRA-wide Consensus

    Linda Wagner-Weiner 1, Vidya Sivaraman 2, Karen James 3, Eric Yen 4, Kathleen O'Neil 5, Dana Gerstbacher 6, Ann Marie Szymanski7, Kimberly Morishita 8 and David Cabral 9 for the CARRA investigators, 1University of Chicago, Chicago, Illinois, 2Division of Rheumatology, Nationwide Children's Hospital, Bexley, 3University of Utah, 84113, Utah, 4UCLA, Los Angeles, California, 5University of Indiana School of Medicine, Indianapolis, Indiana, 6Stanford University School of Medicine, Palo Alto, California, 7Tampa, Florida, 8University of British Columbia - Vancouver, Vancouver, British Columbia, Canada, 9BC Children's Hospital and University of British Columbia, Vancouver, British Columbia, Canada

    Background/Purpose: Randomized trials for pediatric ANCA-associated vasculitis (ped-AAV) have not been feasible because of its rarity, therefore adult treatment strategies are usually adapted for children.…
  • Abstract Number: 113 • 2020 Pediatric Rheumatology Symposium

    Evaluation of B-cell Depletion with Rituximab and IVIG Concurrent Treatment in Pediatric Autoimmune Brain Disease

    Alexis Wilsey1, Heather Van Mater 2 and Laura Cannon 2, 1Durham, 2Duke University, Durham

    Background/Purpose: Rituximab is standard therapy in treating autoimmune brain disease (ABD) including refractory autoimmune encephalitis (AE) and Neuromyelitis Optica Spectrum Disease (NMOSD). Recommendations for continuing…
  • Abstract Number: 143 • 2020 Pediatric Rheumatology Symposium

    Immunological Profiles Following Treatment with Rituximab in Autoimmune Disease

    Laura Cannon 1, Stephanie Johannes1 and Jeffrey Dvergsten 2, 1Duke University, Durham, 2Duke University Hospital, Hillsborough

    Background/Purpose: Autoimmune diseases, including systemic lupus erythematosus (SLE), juvenile dermatomyositis (JDM), and Autoimmune Encephallitis (AE) arise due to dysregulation of the immune system and a…
  • Abstract Number: 2634 • 2019 ACR/ARP Annual Meeting

    ANCA Response upon Rituximab or Cyclophosphamide in ANCA-associated Vasculitis Patients

    Laura van Dam1, Ebru Dirikgil 2, Edwin Bredewold 2, Argho Ray 2, Ton Rabelink 2, Cees van Kooten 2 and Onno Teng 2, 1LUMC, Leiden, Zuid-Holland, Netherlands, 2LUMC, Leiden, Netherlands

    Background/Purpose: Recent studies have demonstrated that in patients with anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV) with successful remission-induction (RI) after cyclophosphamide (CYC), maintenance treatment with…
  • Abstract Number: 2902 • 2019 ACR/ARP Annual Meeting

    The Use and Safety of Rituximab in Connective Tissue Disease Associated Interstitial Lung Disease

    Christopher Mesa1, Snehaja Yadlapati 1 and Myriam Guevara 2, 1Louisiana State University Health Science Center, New Orleans, LA, 2Louisiana State University School of Medicine, New Orleans

    Background/Purpose: Interstitial Lung Disease (ILD) is the most common lung manifestation in Connective Tissue Diseases (CTD). It is present in most types of CTD, such…
  • Abstract Number: 2911 • 2019 ACR/ARP Annual Meeting

    A Randomised, Open Labelled Clinical Trial to Investigate Synovial Mechanisms Determining Response – Resistance to Rituximab versus Tocilizumab in Rheumatoid Arthritis Patients Failing TNF Inhibitor Therapy

    Frances humby 1, Maya H. Buch 2, Patrick Durez 3, Myles Lewis 1, Michele Bombardieri 1, Hasan Rizvi 4, Stephen Kelly 4, Liliane Fosatti 1, Rebecca Hands 1, Giovanni Giorli 1, Arti Mahto 1, Carlomaurizio Montecucco 5, Bernard Lauwerys 6, Vasco Romao 7, Arthur Pratt 8, Serena Bugatti 9, Nora Ng 10, Felice Rivellese 1, Pauline Ho 11, Mattia Bellan 12, Mattia Congia 13, Patrick Verschueren 14, Pier Paolo Sainaghi 12, Nagui Gendi 15, Bhaskar Dasgupta 16, Alberto Cauli 17, Piero Reynolds 18, Juan Cañete 19, Robert J. Moots 20, Peter Taylor 21, Christopher Edwards 22, John Isaacs 8, Peter Sasieni 23, João Eurico Fonseca 24, Ernest Choy 25 and Costantino Pitzalis26, 1Queen Mary University of London, London, United Kingdom, 2University of Leeds & NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom, 3Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, UCL Saint-Luc, Brussels, Belgium, 4Barts Health NHS Trust, London, United Kingdom, 5Department of Rheumatology, IRCCS Policlinico S. Matteo Foundation, University of Pavia, Pavia, Italy, Pavia, Italy, 6University of Louvain, Louvain, Belgium, 7University of Lisbon, Lisbon, Portugal, 8University of Newcastle, Newcastle, United Kingdom, 9University of Pavia, Pavia, Italy, 10Guys and St Thomas NHS Trust, London, United Kingdom, 11University of Manchester, Manchester, United Kingdom, 12University of Novara, Novara, Italy, 13University of Cagliari, Cagliari, Italy, 14University of Leuven, Leuven, Belgium, 15Basildon Hospital NHS Trust, Basildon, United Kingdom, 16Southend University Hospital, NHS Foundation Trust, Westcliff-on-Sea, United Kingdom, 17Rheumatology Unit, University Clinic AOU and University of Cagliari, Cagliari, Italy, 18Homerton University NHS Trust, London, United Kingdom, 19Rheumatology Department, Hospital Clínic and IDIBAPS,, Barcelona, Spain, 20Institute of Ageing and Chronic Disease, Liverpool, United Kingdom, 21University of Oxford, Oxford, United Kingdom, 22University of Southampton, Southampton, United Kingdom, 23Kings College London, London, United Kingdom, 24Rheumatology and Bone Diseases Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte; Unidade de Investigação em Reumatologia, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa; Centro Académico de Medicina de Lisboa; Lisbon, Portugal., Lisbon, Portugal, 25Cardiff University School of Medicine, Cardiff, United Kingdom, 26Centre for Experimental Medicine & Rheumatology, Queen Mary University of London, London, United Kingdom

    Background/Purpose: Although biologic therapies have transformed the outlook for rheumatoid arthritis (RA), the lack of a major treatment response in over 50% of patients, the…
  • Abstract Number: 309 • 2019 ACR/ARP Annual Meeting

    Increasing Capacity and Reducing Costs of Rituximab Administration

    Zachary Wallace1, Tyler Harkness 1, Kimberly Blumenthal 1, Hyon K. Choi 2, John Stone 3 and Rochelle Walensky 1, 1Massachusetts General Hospital, Boston, 2Massachusetts General Hospital, Boston, MA, 3Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA

    Background/Purpose: Rituximab (RTX) is associated with a large cost burden on the healthcare system and treatment delays that often exceed one month because the long…
  • Abstract Number: 383 • 2019 ACR/ARP Annual Meeting

    Retroperitoneal Fibrosis- a Single Center Experience

    Mert Oztas1, Emir Cerme 2, Izzet Altun 3 and Serdal Ugurlu 4, 1Istanbul University-Cerrahpasa,Department of Medicine, Division of Rheumatology, Istanbul, Turkey, 2Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey, 3Mayo Clinic, Scottsdale, AZ, 4Istanbul University - Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, istanbul, Turkey

    Background/Purpose: Idiopathic retroperitoneal fibrosis (iRPF) is a rare, chronic, progressive disorder of unknown etiology and characterized by the presence of inflammatory and fibrous retroperitoneal tissue…
  • Abstract Number: 537 • 2019 ACR/ARP Annual Meeting

    Efficacy and Safety Results from a Randomized Double-Blind Study That Compared the Proposed Biosimilar ABP 798 with Rituximab in Subjects with Moderate to Severe RA

    Gerd Burmester1, Edit Drescher 2, Pawel Hrycaj 3, David Chien 4, Zhiying Pan 4 and Stanley Cohen 5, 1Charité—University Medicine Berlin, Berlin, Germany, 22Veszprém Csolnoky Ferenc County Hospital, Veszprém, Hungary, 3Koscian Municipal Hospital, Koscian, Poland, 4Amgen, Thousand Oaks, CA, 5Metroplex Clinical Research Center, Dallas, TX

    Background/Purpose: ABP 798 is being developed as a biosimilar to rituximab, a CD20-directed cytolytic antibody that is approved in the US and EU for treatment…
  • Abstract Number: 539 • 2019 ACR/ARP Annual Meeting

    A Randomized Double-Blind Study Comparing Pharmacokinetics (PK) and Pharmacodynamics (PD) of ABP 798 with Rituximab in Subjects with Moderate to Severe RA

    Gerd Burmester1, Stanley Cohen 2, David Chien 3, Vincent Chow 3 and Zhiying Pan 3, 1Charité—University Medicine Berlin, Berlin, Germany, 2Metroplex Clinical Research Center, Dallas, TX, 3Amgen, Thousand Oaks, CA

    Background/Purpose: ABP 798 is being developed as a biosimilar to rituximab, a CD20-directed cytolytic antibody that is approved in the US and EU for treatment…
  • Abstract Number: 793 • 2019 ACR/ARP Annual Meeting

    Rituximab for Rapidly Progressive Juvenile Systemic Sclerosis: A Proof-of-concept Study in Four Patients

    Roberto Dal Pozzolo 1, Alessandra Meneghel 1, Biagio Castaldi 1, Giorgia Martini 1, Renzo Marcolongo 2 and Francesco Zulian3, 1Dept. of Woman's and Child's Health, University of Padua, Italy, Padua, Italy, 2Clinical Immunology, Dept. of Medicine, University of Padua, Padua, Italy, 3Department of Woman and Child Health, University of Padua, Italy, Padova, Italy

    Background/Purpose: Juvenile Systemic Sclerosis (JSSc) is a rare multi-systemic disease characterized by fibrous changes of the skin and internal organs [1]. Patients with “rapidly progressive”…
  • Abstract Number: 806 • 2019 ACR/ARP Annual Meeting

    A Randomized, Controlled Trial of Rituximab versus Azathioprine After Induction of Remission with Rituximab for Patients with ANCA-associated Vasculitis and Relapsing Disease

    Rona Smith1, David Jayne 2 and Peter Merkel 3, 1University of Cambridge, Cambridge, England, United Kingdom, 2Vasculitis and Lupus Clinic, Addenbrooke’s Hospital, University of Cambridge, UK, Cambridge, United Kingdom, 3University of Pennsylvania, Philadelphia

    Background/Purpose: Rituximab is an effective therapy for induction of remission in ANCA-associated vasculitis (AAV).  However, the effect of rituximab is not sustained, and relapse rates…
  • Abstract Number: 845 • 2019 ACR/ARP Annual Meeting

    Comparison of Rituximab-Associated Hypogammaglobulinemia Rates in Patients with Systemic Rheumatologic Conditions

    Stefanie Wade1 and Vasileios Kyttaris 1, 1Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA

    Background/Purpose: Rituximab (RTX) is used in a wide variety of rheumatic disease. Emerging guidelines suggest measuring immunoglobulins (Ig) at pre-treatment screening and prior to repeat…
  • Abstract Number: 882 • 2019 ACR/ARP Annual Meeting

    Serum Anti-Vimentin Autoantibodies May Uniquely Predict Response to Therapy in Lupus Nephritis

    Andrew Kinloch1, Matthew Cascino 2, Jian Dai 3, Rene Bermea 1, Kichul Ko 1, Margaret Vesselits 4, Maureen Legendre 5, Michael Okoreeh 1, David Markovitz 5, Leonard Dragone 6, Michael Townsend 3 and Marcus Clark 1, 1University of Chicago, Chicago, IL, 2Genentech, Inc., San Fransisco, CA, 3Genentech, San Fransisco, CA, 4University of Chicago, Chicago, 5University of Michigan, Ann Arbor, MI, 6UCSF, San Fransisco, CA

    Background/Purpose: Tubulointerstitial inflammation (TII) in lupus nephritis (LN) is associated with a worse prognosis. Vimentin, a cytoplasmic antigen, is commonly targeted by in situ activated…
  • 1
  • 2
  • 3
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
This site uses cookies: Find out more.